

May Insights

Register Today for the HESI Annual Meeting!

Registration is open for the 7–8 June 2016 HESI Annual Meeting in Arlington, Virginia. Don't miss this year's exciting science sessions: (I) "HESI Science from Research to Application" and (II) "Meeting Current and Pending Human and Environmental Health Challenges." View the current meeting agenda at HESI's website. To register and make your hotel reservations, please click here. Please contact Ms. Cyndi Nobles (cnobles@hesiglobal.org) with any questions.



HESI Science to Be Featured at Upcoming Conferences

HESI at the Society of Environmental Toxicology and Chemistry (SETAC) Europe Annual Meeting

The 26th SETAC Europe Annual Meeting will be held 22–26 May 2016 in Nantes, France. Visit the <u>meeting website</u> to learn more. HESI committee and staff work will be well represented at the meeting! Contact Michelle Embry (<u>michelle.embry@hesiglobal.org</u>) for more information.

Sunday, 22 May 2016

Workshop on Trophic Magnification Factors (TMFs) and Environmental Specimen Banks (sponsored by the HESI Bioaccumulation Technical Committee)

Tuesday, 24 May 2016

• Platform 231: In Vitro to In Vivo Extrapolation of Hepatic Metabolism in Fish: An Inter-Laboratory Comparison of In Vitro Methods (platform presentation by Kellie Fay, USEPA, on behalf of the Bioaccumulation Technical Committee)

- Platform 233: Ecological Threshold for Toxicological Concern (eco-TTC) Assessing the
 potential of a new tool for environmental hazard assessment (platform presentation by Amy
 Beasley, Dow Chemical, on behalf of the Animal Alternatives in ERA Technical Committee)
- Poster TU 078: Concepts, Tools, and Strategies for Effluent Testing: An International Survey (poster presentation by Michelle Embry, HESI, on behalf of the Animal Alternatives in ERA Technical Committee)
- Poster TU 082: A Critical Review of Mode of Action (MOA) Assignment Classifications for Ecotoxicology (poster presentation by Michelle Embry, HESI, on behalf of the Animal Alternatives in ERA Technical Committee)
- Poster TU 087: Statistical Approach to Inform the Study Design of an Inter-laboratory
 Comparison of In Vitro Methods (S9 Fraction and Isolated Cryopreserved Hepatocytes) to
 Estimate Hepatic Metabolism in Fish) (poster presentation by Michelle Embry on behalf of the
 Bioaccumulation Technical Committee)
- Poster TU 090: The Use of Trout Liver S9 Fraction and Cryopreserved Trout Hepatocytes in Substrate Depletion Assays for the Evaluation of Xenobiotic Biotransformation by Fish (poster presentation by Karla Johanning, KJ Scientific, on behalf of the Bioaccumulation Technical Committee)

Wednesday, 25 May 2016

- Platform 393: Building Improved In Vitro Exposure Assessment Capability: Towards the
 Development and Implementation of Enhanced QIVIVE Tools (platform presentation by Todd
 Gouin, Unilever; Michelle Embry, HESI, co-author)
- Platform 394: Examining Underlying Assumptions When Translating In Vitro Bioassay Results
 to In Vivo Conditions (platform presentation by Jon Arnot, ARC; Michelle Embry, HESI, coauthor)

HESI Emerging Issues Sub-Committee Co-Chairs Invited to Present at the International Society for Stem Cell Research (ISSCR) Webinar "Translational Know-How" Series

Bill Shingleton (GE Healthcare) and Gregory Mullen (King's College London), co-chairs of the Cell Therapy – TRAcking, Circulation, & Safety (CT-TRACS) Subcommittee, will present on May 24, at 1 pm EST, on the topic "Securing the Safety of Cellular Therapies to Realize Their Potential." Details will be published on the ISSCR website. For additional information, contact Lucilia Mouriès (lmouries@hesiglobal.org).

HESI at the Green Chemistry and Engineering Conference

The 20th Annual Green Chemistry and Engineering Conference (<u>www.gcande.org</u>) will take place in Portland, Oregon, on 14–16 June 2016. On June 15, the HESI Sustainable Chemical Alternatives Committee will present "HESI Pilot Project: Testing a Qualitative Approach for Incorporating Exposure Into Alternatives Assessment" during the Alternatives Assessment & De Novo Design session. For additional information, contact Jennifer Y. Tanir (<u>itanir@hesiglobal.org</u>).

HESI at the 42nd Annual Summer Meeting of the Toxicology Forum

Session: "Refined Applications of Toxicogenomics in Safety Assessment"
Organized by the HESI Genomics Committee
24–28 July 2016
Salt Lake City, Utah

Visit the meeting website or contact Raegan B. O'Lone (rolone@hesiglobal.org) for details.

Teratology Society 2016 Annual Meeting

Session: "Ontogeny of FcRn in Gestation Across Species"
Organized by the HESI DART Technical Committee
Wednesday, 29 June 2016
San Antonio, Texas

Visit the meeting website or contact Connie Chen (cchen@hesiglobal.org) for details.

Call for Abstracts

The HESI Sustainable Chemical Alternatives Committee is chairing a platform session on Business Examples of Chemical Alternatives Assessment at the <u>SETAC North America Annual Meeting</u>, 6–10 November 2016 in Orlando, Florida. This session will emphasize the sharing of practices in industry at different parts of the supply chain, by manufacturers, formulators, and retailers. Presentations on advances in chemical substitutions from the public sector are also welcome. The meeting will provide a forum for sharing best practices of chemical alternatives assessment. Abstract submission is open until 8 June 2016. Please contact Jennifer Y. Tanir (itanir@hesiglobal.org) for more information.

Open Surveys

- Male Reproductive Toxicology. The DART Technical Committee has launched a survey toward understanding the predictivity of adverse findings in nonclinical male fertility studies to clinical outcomes in men. The survey is open to all who are willing to contribute data. To learn more about or to participate in the survey, please contact Connie Chen (cchen@hesiglobal.org). Survey responses will be accepted on a rolling basis through 30 June 2016.
- Nonclinical Neonatal Models. The DART Technical Committee has formed a workgroup to understand the best use of nonclinical approaches for neonatal therapeutics. In order to gain a better understanding of the scope and application of available approaches across industry, regulatory, and academic institutes, you are invited to submit your experience with current nonclinical models of drug development intended for neonatal pediatric diseases via an open survey. Contact Connie Chen (cchen@hesiglobal.org) to learn more or to participate in the survey.

FROM THE EXECUTIVE DIRECTOR

I look forward to seeing many of you at next month's HESI Annual Meeting. We've got a terrific lineup of science to share with you. Register now and encourage your colleagues to join us as well. See you soon!

Spil D. Pethit

ILSI Health and Environmental SciencesInstitute (HESI)

1156Fifteenth Street, NW 2nd Floor Washington, DC 20005-1743 | 202.659.3306 | 202.659.3617 | HESI@hesiglobal.org | www.hesiglobal.org

STAY CONNECTED





